Healthcare >> Analyst Interviews >> May 6, 2002
CLAUDE CAMIR has had a 20-year career covering the pharmaceutical,
biotech and medical devices industries, including the last four years as
a healthcare analyst. His coverage of the sector includes biotech,
service and manufacturing companies in Canada and the US. He has worked
in senior and managerial positions covering marketing, finance and
business development activities for Abbott Laboratories, Aventis (Rhone-
Poulenc Rorer) and Biochem Pharma. He has been involved extensively in
technology valuation, financing and mergers and acquisitions in North
America and Europe. He has received his B. Comm (Finance/Accounting)
degree from the University of Sherbrooke. He is currently enrolled in
the MBA program at the Universit_ du Qu_bec in Montreal and the CFA
program level 2 (exam scheduled for June 2003). Profile
North American counterpart?
Mr. Camir: I think nothing really differentiates the two
countries' biotech efforts. I think we're
